Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

11 evidence topics · 11 sources

Summary: response by prior advanced therapy exposure

In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.

Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy

“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024

“In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote